Apellis Pharmaceuticals Stock In The News

APLS Stock  USD 30.77  3.02  10.88%   
Our overall analysis of Apellis Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Apellis Pharmaceuticals. The specific impact of Apellis Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Apellis Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Apellis Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Apellis Pharmaceuticals Backtesting and Apellis Pharmaceuticals Hype Analysis.
For more information on how to buy Apellis Stock please use our How to Invest in Apellis Pharmaceuticals guide.

Apellis Pharmaceuticals Today Top News and Investor Outlook

Yahoo News
Syfovre's Competitive Edge Highlights Bright Future For Apellis Pharmaceuticals, Analyst Initiates With Bullish Pitch
https://finance.yahoo.com/news/syfovres-competitive-edge-highlights-bright-185659857.html
 Bullish
Yahoo News
Apellis Announces Oral Presentation at A...
https://finance.yahoo.com/news/apellis-announces-oral-presentation-american-110000261.html
 Neutral
Yahoo News
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://finance.yahoo.com/news/apellis-pharmaceuticals-announces-inducement-grants-200500971.html
 Bullish
Yahoo News
Should You Hold Apellis Pharmaceuticals (APLS)?
https://finance.yahoo.com/news/hold-apellis-pharmaceuticals-apls-141939686.html
 Bullish
Yahoo News
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
https://finance.yahoo.com/news/apellis-pharmaceuticals-host-fireside-chat-110000391.html
 Bullish
Yahoo News
Apellis Stock Down as Eye Drug Faces Third CHMP Rejection in the EU
https://finance.yahoo.com/news/apellis-stock-down-eye-drug-152500211.html
 Bullish
Yahoo News
Apellis Stock Hammered After Eye Drug Gets A Third European Rejection
https://finance.yahoo.com/m/26cd5c0d-fe4d-3b0c-b168-57d99afe6bc5/apellis-stock-hammered-after.html
 Bearish
Yahoo News
Apellis European Rejection for Vision Treatment Dents Revenue Growth, Stock Performance, Wedbush Says
https://finance.yahoo.com/news/apellis-european-rejection-vision-treatment-172757098.html
 Bullish
Yahoo News
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
https://finance.yahoo.com/news/apellis-receives-negative-chmp-opinion-090000636.html
 Neutral
Yahoo News
Apellis Pharmaceuticals, Inc. (APLS): Among Hedge Funds’ Top Biotech Stock Picks
https://finance.yahoo.com/news/apellis-pharmaceuticals-inc-apls-among-233645588.html
 Bullish

Apellis Pharmaceuticals Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Apellis and other traded companies coverage with news coverage. We help investors stay connected with Apellis headlines for the 25th of November to make an informed investment decision based on correlating the impacts of news items on Apellis Stock performance. Please note that trading solely based on the Apellis Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Apellis Pharmaceuticals' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Apellis Pharmaceuticals investors visualize upcoming and past events in order to time the market based on Apellis Pharmaceuticals noise-free hype analysis.
Apellis Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Apellis earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Apellis Pharmaceuticals that are available to investors today. That information is available publicly through Apellis media outlets and privately through word of mouth or via Apellis internal channels. However, regardless of the origin, that massive amount of Apellis data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Apellis Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Apellis Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Apellis Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Apellis Pharmaceuticals alpha.

Apellis Largest EPS Surprises

Earnings surprises can significantly impact Apellis Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-08-01
2024-06-30-0.32-0.280.0412 
2024-05-07
2024-03-31-0.47-0.420.0510 
2018-04-30
2018-03-31-0.33-0.43-0.130 
2018-03-19
2017-12-31-0.48-0.6-0.1225 
2018-07-31
2018-06-30-0.47-0.61-0.1429 
2024-11-05
2024-09-30-0.3-0.4624-0.162454 
View All Earnings Estimates

Apellis Pharmaceuticals Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Apellis Pharmaceuticals Stock. Current markets are strongly bullish. About 86% of major world exchanges and indexes are currently up. See today's market update for more information.
Investing News at Macroaxis
21st of November 2024
Morgan Stanley sets Apellis stock at Equalweight
at investing.com 
Gurufocus Stories at Macroaxis
15th of November 2024
Acquisition by Karen Lewis of 24666 shares of Apellis Pharmaceuticals at 66.3 subject to R...
at gurufocus.com 
Yahoo News
12th of November 2024
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Confere...
at finance.yahoo.com 
insidermonkey News
7th of November 2024
Apellis Pharmaceuticals, Inc. Q3 2024 Earnings Call Transcript
at insidermonkey.com 
Gurufocus Stories at Macroaxis
6th of November 2024
Apellis Pharmaceuticals Inc Q3 2024 Earnings Call Highlights Revenue Surge and ...
at gurufocus.com 
zacks News
5th of November 2024
Apellis Pharmaceuticals Reports Q3 Earnings What Key Metrics Have to Say
at zacks.com 
Yahoo News
4th of November 2024
Apellis Pharmaceuticals Inc Q3 2024 Earnings Report Preview What to Look For
at finance.yahoo.com 
news
17th of October 2024
Apellis Pharmaceuticals Now Covered by Analysts at Scotiabank
at thelincolnianonline.com 
Macroaxis News: globenewswire.com
20th of September 2024
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy in the EU ...
at globenewswire.com 

Apellis Pharmaceuticals Investors Sentiment

The influence of Apellis Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Apellis. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Apellis Pharmaceuticals' public news can be used to forecast risks associated with an investment in Apellis. The trend in average sentiment can be used to explain how an investor holding Apellis can time the market purely based on public headlines and social activities around Apellis Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Apellis Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Apellis Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Apellis Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Apellis Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Apellis Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Apellis Pharmaceuticals' short interest history, or implied volatility extrapolated from Apellis Pharmaceuticals options trading.

Additional Tools for Apellis Stock Analysis

When running Apellis Pharmaceuticals' price analysis, check to measure Apellis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apellis Pharmaceuticals is operating at the current time. Most of Apellis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Apellis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apellis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Apellis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.